Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years by Rowe, William J
© 2010 Rowe, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nephrology and Renovascular Disease 2010:3 123–127
International Journal of Nephrology and Renovascular Disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
123
COMMeNTARy
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJNRD.S13032
Long space missions, gene therapy, and the vital 
role of magnesium: a three-pronged plan for the 
next 50 years
William J Rowe
Medical University of Ohio,  
Toledo, OH, USA
Correspondence: William J Rowe 
1485 Bremerton La., Keswick,  
VA 22947, USA 
Tel +1 434 984 0079 
email rowerun@aol.com
Abstract: Since pharmaceuticals cannot be used in space until liver and kidney dysfunctions 
are corrected, and with invariable malabsorption, it appears there is no alternative other than 
to use subcutaneous magnesium (Mg) replacements in the presence of deficiencies and use 
of gene therapy. I suggest beginning with the correction of as many as four gene deficiencies: 
atrial natriuretic peptide (ANP), nitric oxide (NO), vascular endothelial growth factor (VEGF), 
and erythropoietin (EPO), all as well as Mg related to perfusion and angiogenesis. There is no 
evidence of significant lunar radiation levels in the absence of a solar storm. It could then be 
determined whether this has resulted in correction of liver and kidney dysfunction. If this per-
sists, serial additions of gene therapy will be required determining the effect of each individual 
gene trial on organ function. Microgravity and endothelial gaps with leaks trigger reduced 
plasma volume. Partial correction by use of a plasma volume substitute and development of a 
delivery device may reduce complexity of gene therapy. Research would be conducted both on 
Earth and in microgravity, with the development of subcutaneous pharmaceuticals and Mg, and 
a space walk-reliable subcutaneous silicon device, given that no replenishable subcutaneous 
device is presently available. A three-pronged approach provides a plan for the next 50 years: 
A. complete correction of a Mg deficit; B. partial replacement with plasma volume substitutes, 
and C. multiple gene factor strategy.
Keywords: malabsorption, gene therapy, kidneys, liver, magnesium, microgravity, space 
flight
The most sacred of the duties of a government [is] to do equal and impartial justice 
to all its citizens.
—Thomas Jefferson, 1816.
Introduction
It has been 50 years since humans ventured into space. Will the next 50 years bring 
solutions to the vascular hazards resulting from both microgravity and hypokinesia 
(restricted movements)? Some animals that live all of their lives in caves cannot adjust 
to living outside the cave. Are humans spared the restrictions of nature? During space 
flight, the endothelium is vulnerable to injuries complicating oxidative stress mechanisms 
with inflammation, triggered by catecholamine, angiotensin, and endothelin elevations, 
along with reductions in magnesium (Mg) ions, atrial natriuretic peptide (ANP), and 
nitric oxide (NO), with resulting vicious cycles. With impaired angiogenesis second-
ary to a Mg deficit,1 and with impaired perfusion of the liver and kidneys and, in turn, 
insufficient metabolism and excretion of pharmaceuticals, how can an acute myocardial International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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infarction, for example, be treated after perhaps 20 months of 
space flight? It has been noted1 that the pharmacokinetic and 
pharmacodynamics of medications may well be influenced 
by the effects of microgravity, and emphasized the effects of 
microgravity on blood flow in the liver. During the 438-day 
Mir mission, the cosmonaut’s cyclic guanosine monophosphate 
(cGMP) was not detectable after five months in space and 
did not return to premission levels until three months after 
return from his space flight. cGMP is a second messenger 
of both NO and ANP.2,3 In the presence of dust inhalation, in 
such habitats as Apollo 15, combined with space flight and 
endothelial dysfunction/injury,4–6 these factors can lead to 
extraordinary elevations of stress test hypertension, even in 
missions of less than two weeks’ duration and in the absence 
of significant exposure to radiation.1 Techniques to prevent 
inhalation of dust in the environment may eventually be 
successful, first by   removing the space suit before entry and 
backing into the habitat or module. In addition, ultrafine dust 
particles (,100 nm) might be removed from the space suit by 
electrostatic precipitators. Even without dust exposure, very 
prolonged space flight may lead to renovascular hypertension 
with evidence of self-limiting proteinuria, impairment in renal 
concentrating ability, and elevations of serum creatinine.1 
In addition, with space flight, there is reduced diurnal blood 
pressure variation which portends kidney disease. Indeed, on 
earth, the endothelial repair process is somewhat impaired after 
the age of 30 years, and these repair mechanisms are further 
impaired with space flight.1,4,5 Pharmaceuticals cannot be used, 
other than for emergencies, because of invariable malabsorp-
tion, and potential impairment in hepatic and renal function, 
so that those in a space flight would not be able to metabolize 
or excrete pharmaceuticals satisfactorily, if the mission was 
sufficiently prolonged. Furthermore, at this time, there is no 
suitable, replenishable, subcutaneous silicon device to adminis-
ter medications. In addition, some pharmaceuticals deteriorate 
during space flight, but why this occurs is unknown. Despite 
decreased sensitivity of serum Mg, it has been reported1 that 
significantly decreased serum Mg levels (P , 0.0001) after 
shuttle missions. Both too much4 and too little5 exercise will 
decrease these Mg levels. In the early weeks of a mission, there 
is a 1%–2% loss of bone per month and loss of skeletal muscle 
mass, both of which are storage sites for Mg, with further loss 
from malabsorption. Mg is required for at least 300 enzymatic 
reactions,   including those which metabolize drugs. Mg is also 
an antioxidant and calcium blocker.1
All the enzymes that metabolize vitamin D require Mg. 
Vitamin D, which is depleted in space, is required for bone 
metabolism and protects the cardiovascular system. Since 
deficiencies of vitamin D occur in one-third to one-half of 
otherwise healthy adults, and are conductive to elevations 
of vessel constrictors and in turn, hypertension, variations 
in vitamin D levels both prior to and during a mission may 
account at least partially for the discrepancies in space flight 
blood pressures. Reductions, no change, and significant 
elevations of blood pressures have all been reported.1 
A request through the Freedom of Information Act (FOIA) 
in 2007 showed that Irwin possibly had endothelial dysfunc-
tion prior to his Apollo 15 mission, and that from one month 
before lift-off, his resting blood pressure was as high as 
145/110 mmHg. A subsequent request for FOIA stress test 
data regarding Conrad (Apollo 12) and Shepard (Apollo 14) 
was of no value because the National Aeronautics and Space 
Administration (NASA) was unable to provide sufficient data 
for comparison with those from Irwin. Furthermore, NASA 
will only provide data for astronauts who are deceased.
Gene therapy
Although the entire body is in jeopardy during a space 
flight, obviously it would be absurd to suggest that for a very 
long mission, replacement of a large portion of the genome 
would be required. However, it is reasonable to begin by 
using gene therapy to correct four deficiencies, ie, ANP, 
NO, erythropoetin (EPO), and vascular endothelial growth 
factor (VEGF),7–10 the latter being triggered by space flight, 
with thrombocytopenia and diminished VEGF expression 
complicating space flight insulin resistance, and Mg deficit 
playing a role.1 Thrombocytopenia may be induced by platelet 
adhesions and aggregation, which is prevented by NO,2,10 and 
platelets are the primary source of VEGF.1 Red blood cells, 
which function as antioxidants, are reduced by about 10% 
even on short missions, along with invariable dehydration 
with, in addition, decreased thirst and invariable reductions 
of plasma volume, for example, which are reduced by 10% 
after a nine-day mission. Radiation was not a factor on Apollo 
missions.11 As for gene therapy, a recent editorial suggests 
that prospects for continuing advancement of gene therapy 
to wider applications remain strong.12 However, it is appar-
ent that because the molecular mechanisms responsible for 
angiogenesis are very complex, a “multiple factor strategy” 
will be required.13
Mg deficiency during a space flight plays an important 
role in renal disease. An experimental Mg deficiency has been 
shown to cause hypertrophy of the juxtaglomerular apparatus, 
resulting in aldosterone secretion, which in turn increases 
Mg loss and creates vicious cycles. These vicious cycles can 
develop from Mg ion deficits, with resultant catecholamine International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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elevations and an increased angiotensin effect. The latter 
can contribute to an upregulated intrarenal renin-angiotensin 
system with hypertension (see Figure 1). However, if renal 
insufficiency occurs, Mg replacement will have to be closely 
monitored.1 Focusing on correction of peripheral vascu-
lar complications during space flight, for example, in the 
presence of a 40% reduction of calf blood flow in micrograv-
ity and doubling of calf vascular resistance,1 the results with 
intramuscular gene transfer of VEGF have been encouraging, 
with an increase in collateral vessels around the injection 
sites during a nine-month follow-up study.14,15
What has been the space flight experience with delivery of 
gene therapy systemically? Gene therapy was first suggested 
a decade ago for treating astronauts with space-induced 
anemia.16 More recent earth-based studies suggest that 
space flight-gene therapy may be useful for correcting ANP 
deficiencies of .40% after 7–12 space flight days.1 Space 
flight deficiencies in ANP may play an important role, because 
on earth, dust inhalation does not cause the degree of hyper-
tension Irwin experienced.17 A decrease in renal blood flow 
may be significantly reversed following NO synthase gene 
transfer, with improvement in renal function.1,10 It is clear that 
with gene therapy we are only at the beginning, with possibly 
decades of gene therapy research ahead, involving studies both 
on earth and at the International Space Station. No meaning-
ful research seems to have been conducted with gene therapy 
to offset the vascular complications of space flight. There are 
numerous problems with gene therapy, first and foremost, 
finding a suitable vector. The focus has been primarily in search 
of a virus vector which would penetrate into the nucleus without 
causing, eg, immune reactions, severe hypotension, or shock.7,10 
Transfection efficacy has been found to be only temporary, and 
there may be pathologic overgrowth of endothelial cells.8 Fur-
thermore, McCarthy et al10 have emphasized that reproducibility 
of positive results has yet to be demonstrated conclusively. It is 
important to stress that there is no evidence from Berry’s lunar 
studies that the various Apollo complications were triggered 
by significant radiation exposure,11 nor is there evidence at this 
time that the deterioration of some pharmaceuticals during 
space flight is radiation-related. However, during a solar proton 
storm the levels would be much higher. On earth, with head-
down-tilt bed rest studies, the concentration of cGMP is also 
decreased.2 Therefore, one can assume that the impairment 
in liver and kidney function may be entirely due to vascular 
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Figure 1 Proposed mechanisms for space flight-related vascular complications requiring magnesium repacement and possible correction of at least four gene deficiencies.
Abbreviations: ANP, atrial natriuretic peptide; ePO, erythropoietin; NO, nitric oxide; VeGF, vascular endothelial growth factor.International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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insults.1 This must be corrected, and pharmaceuticals, other 
than for symptomatic treatment or emergencies, cannot be 
administered with any degree of safety.
In cardiac tissue, hypokinesia and space flight studies in 
experimental animals have shown endothelial projections 
and narrowing of small vessels with occlusions.1 Gaps, with 
endothelial projections, can cause plasma to leak from   vessels.18 
This intensifies loss of plasma volume from microgravity, 
beginning soon after lift-off1 (see Figure 1). The invariable 
plasma volume reduction in microgravity triggers anemia 
associated with reduced EPO levels.19 In addition to correcting 
anemia, EPO may contribute to angiogenesis along with VEGF, 
NO, ANP, and Mg.1,7–10,13,15,19–21 It has been shown that serum 
EPO, suppressed immediately after launch, remained low dur-
ing a nine-day shuttle mission.19 Correction of EPO deficiency 
has also been shown to be cardioprotective. However, there 
is a risk of both hypertension and thrombosis with chronic 
exposure to EPO gene therapy.21
On the other hand, although gene therapy with both NO 
and ANP can lead to hypotension if the expression of gene 
therapy is not tightly regulated to the target site,1 the risk of 
inducing shock may be greater with ANP because it directly 
inhibits the renin–angiotensin–aldosterone axis and the sympa-
thetic nervous system. Because ANP is significantly reduced, 
partially as a result of reduction in plasma volume, and Mg is 
probably necessary for both ANP synthesis and release, this 
Mg deficiency must be corrected first, using a yet to be devel-
oped subcutaneous silicon device, which can be replenished 
and would be reliable during strenuous effort, as with space 
walks.22 It is proposed that, after reversal of a Mg deficit1,22–24 
it is worthwhile correcting, as a start, deficiencies of as many 
as four genes, ie, ANP, NO, VEGF, and EPO (see Table 1). If 
this is successful, as indicated by restoration of both liver and 
kidney function, subcutaneous pharmaceuticals can be used.
There is limited experience with both subcutaneous Mg22 
and subcutaneous pharmaceuticals at this time. These will 
require research at the International Space Station. If there 
is still no evidence that organ dysfunction has been offset, 
then additional genes, specifically those enhancing perfusion, 
will have to be administered, one by one, and will require 
decades of research. Because reduced plasma volume is an 
important trigger for deficiencies of both EPO and ANP, 
it seems reasonable to postulate that development of a plasma 
volume substitute25 and a subcutaneous delivery device might 
reduce the complexity of this proposed gene therapy requir-
ing a multifactorial strategy. Furthermore, at least partial 
restoration of plasma volume may reduce the potential for 
hypotension and shock (see Table 1). Epstein et al13 have 
stressed how complicated such a process can be in duplicating 
angiogenesis, determining the number of factors required, and 
determining the appropriate sequence and concentration.
Finally, it is conceivable that a centrifuge could be 
developed which would duplicate exactly 1G for travel in 
transit, but the problem would remain of construction of 
habitats and tunnels, and exploration for long periods on the 
surface in a microgravity environment. Furthermore, without 
gene therapy, it seems apparent that man will not be able to 
colonize the Moon, Mars, an asteroid, or beyond.
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